ATE386054T1 - Glycosylierte humane interferon alpha isoform - Google Patents

Glycosylierte humane interferon alpha isoform

Info

Publication number
ATE386054T1
ATE386054T1 AT03791472T AT03791472T ATE386054T1 AT E386054 T1 ATE386054 T1 AT E386054T1 AT 03791472 T AT03791472 T AT 03791472T AT 03791472 T AT03791472 T AT 03791472T AT E386054 T1 ATE386054 T1 AT E386054T1
Authority
AT
Austria
Prior art keywords
interferon alpha
human interferon
alpha isoform
glycosylated human
expression vector
Prior art date
Application number
AT03791472T
Other languages
English (en)
Inventor
Eun-Jung Lee
Hyung-Ki Park
Hyun-Seok Kim
Ji-Sook Park
Yeon-Hyang Kim
Hyune-Soo Lee
Hyung-Kon Koh
Myung-Suk Oh
Original Assignee
Cj Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Corp filed Critical Cj Corp
Application granted granted Critical
Publication of ATE386054T1 publication Critical patent/ATE386054T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03791472T 2002-08-31 2003-08-29 Glycosylierte humane interferon alpha isoform ATE386054T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20020052365 2002-08-31

Publications (1)

Publication Number Publication Date
ATE386054T1 true ATE386054T1 (de) 2008-03-15

Family

ID=36241068

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03791472T ATE386054T1 (de) 2002-08-31 2003-08-29 Glycosylierte humane interferon alpha isoform

Country Status (9)

Country Link
US (1) US7311903B2 (de)
EP (1) EP1549675B1 (de)
JP (1) JP4181543B2 (de)
KR (2) KR20040020817A (de)
CN (1) CN1684979A (de)
AT (1) ATE386054T1 (de)
AU (1) AU2003256125A1 (de)
DE (1) DE60319114T2 (de)
WO (1) WO2004019856A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539960B1 (de) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistente modifizierte interferon alpha polypeptide
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
KR100781666B1 (ko) * 2004-11-02 2007-12-03 신영기 인간 인터페론-베타 변이체
AR078117A1 (es) 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2010017290A1 (en) * 2008-08-05 2010-02-11 The Trustees Of Columbia University In The City Of New York Müllerian inhibiting substance (mis) analogues
US20110105735A1 (en) * 2009-10-29 2011-05-05 Heather Desaire Methods of producing and purifying proteins
WO2011075605A2 (en) * 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated interferon variants and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4931373A (en) * 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US6020465A (en) * 1993-10-22 2000-02-01 University Of Connecticut Recombinant avian type i interferon
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ATE233088T1 (de) * 1996-12-20 2003-03-15 Takeda Chemical Industries Ltd Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
ES2306477T3 (es) * 1997-09-05 2008-11-01 Altus Pharmaceuticals Inc. Cristales de glicoproteina reticulados por carbohidratos.

Also Published As

Publication number Publication date
DE60319114T2 (de) 2008-12-04
JP4181543B2 (ja) 2008-11-19
US7311903B2 (en) 2007-12-25
AU2003256125A1 (en) 2004-03-19
KR100536628B1 (ko) 2005-12-14
US20050019871A1 (en) 2005-01-27
JP2006512058A (ja) 2006-04-13
WO2004019856A2 (en) 2004-03-11
EP1549675B1 (de) 2008-02-13
CN1684979A (zh) 2005-10-19
AU2003256125A8 (en) 2004-03-19
KR20040020830A (ko) 2004-03-09
WO2004019856A3 (en) 2004-07-29
EP1549675A2 (de) 2005-07-06
DE60319114D1 (en) 2008-03-27
EP1549675A4 (de) 2006-05-31
KR20040020817A (ko) 2004-03-09

Similar Documents

Publication Publication Date Title
MXPA01010360A (es) Produccion de proteinas recombinantes en una celula humana.
ATE470702T1 (de) Verfahren zur herstellung von permanenten humanen zelllinien
SG170116A1 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
GB2431404A (en) Peptide
EP2402369A3 (de) Peptidfragmente zur Induzierung der Synthese extrazellulärer Matrixproteine
BRPI0416744A (pt) sistemas de expressão de proteìna aperfeiçoados
MX2009006617A (es) Composiciones que contienen, metodos que involucran y usos de aminoacidos y polipeptidos no naturales.
NO20082716L (no) Sammensetninger og fremgangsmater for fremstilling av en sammensetning
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
ATE462000T1 (de) Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
DE60233049D1 (de) Matrix-anheftungsregionen und verfahren zu deren verwendung
RS53861B1 (en) USE OF HUMAN CELLS ORIGINATING TO MYELOID LEUKEMIA FOR ANTIBODY EXPRESSION
AR020735A1 (es) Un procedimiento para la obtencion de un polipeptido glucosilado a partir de celulas eucarioticas
ATE386054T1 (de) Glycosylierte humane interferon alpha isoform
DE60043777D1 (de) Ngen, die die befestigung von zellen und proteinen mit den sustraten hemmen.
DK1165791T3 (da) Humant cytokin som zalpha-receptor-ligand og anvendelse deraf
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
ATE334998T1 (de) Verfahren zur herstellung cyclischer peptide
TNSN05187A1 (en) Overexpression vector for animal cell
ATE246247T1 (de) Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
DK1194575T3 (da) Modificeret human granulocytkolonistimulerende faktor og fremgangsmåde til fremstilling heraf
WO1997006247A3 (en) Deubiquitinating enzymes that regulate cell growth
WO2004020576A3 (en) Glycosylated human granulocyte colony-stimulating factor (g-csf) isoform
WO2004091475A3 (en) Gaucher disease drugs and methods of identifying same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties